$0.02
(Market cap
$1 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-14 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.4
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
6,328,750
10 Years Aggregate
CFO
$-123.12 Mln
EBITDA
$-127.78 Mln
Net Profit
$-190.94 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vyant Bio (VYNT)
| -72.3 | 9.3 | 16.2 | -71.9 | -75.7 | -65.7 | -60.5 |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Vyant Bio (VYNT)
| -89.6 | -51.3 | -53.5 | -17.2 | -86.9 | 37.0 | -59.1 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vyant Bio (VYNT)
|
0.2 | 1.2 | 0.2 | -13.7 | -6,688.4 | -- | -- | 0.1 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 147.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Vyant Bio (VYNT)
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease,... scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey. Read more
-
Pres, CEO & Director
Mr. John A. Roberts M.B.A., MBA
-
Pres, CEO & Director
Mr. John A. Roberts M.B.A., MBA
-
Headquarters
Cherry Hill, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vyant Bio (VYNT)
What is the current share price of Vyant Bio Inc (VYNT) Today?
The share price of Vyant Bio Inc (VYNT) is $0.19 (NASDAQ) as of 29-Dec-2023 15:40 EDT. Vyant Bio Inc (VYNT) has given a return of -75.72% in the last 3 years.
What is the current PB & PE ratio of Vyant Bio Inc (VYNT)?
Since, TTM earnings of Vyant Bio Inc (VYNT) is negative, P/E ratio is not available.
The P/B ratio of Vyant Bio Inc (VYNT) is 0.12 times as on 29-Dec-2023, a 98 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.18 |
0.41 |
2021 |
-0.17 |
0.25 |
2020 |
-1.75 |
-0.44 |
2019 |
-1.87 |
1.70 |
2018 |
-0.02 |
0.06 |
What is the 52 Week High and Low of Vyant Bio Inc (VYNT)?
The 52-week high and low of Vyant Bio Inc (VYNT) are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of Vyant Bio Inc (VYNT)?
Vyant Bio Inc (VYNT) has a market capitalisation of $ 1 Mln as on 29-Dec-2023. As per SEBI classification, it is a company.
Should I invest in Vyant Bio Inc (VYNT)?
Before investing in Vyant Bio Inc (VYNT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.